— Know what they know.
Not Investment Advice

JBIO NASDAQ

Jade Biosciences, Inc.
1W: -2.1% 1M: -34.0% 3M: -33.7% YTD: -0.3% 1Y: +55.0%
$14.12
+0.35 (+2.54%)
 
Weekly Expected Move ±7.6%
$12 $13 $14 $15 $16
NASDAQ · Healthcare · Biotechnology · Tech Score Sell · Power 32 · $859.3M mcap · 52M float · 2.05% daily turnover · Short 61% of daily vol
Smart Money Score
Moderate 50
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$859.3M
52W Range8.2-28
Volume1,109,790
Avg Volume1,070,885
Beta1.45
Dividend—
Analyst Ratings
4 Buy 0 Hold 0 Sell
Consensus Buy
Company Info
CEOTom Frohlich
Employees55
SectorHealthcare
IndustryBiotechnology
IPO Date2021-06-30
Building 23
Waltham, MA 02453
US
1 916-322-1700
About Jade Biosciences, Inc.

Jade Biosciences, Inc. operates as a biotechnology company that develops therapies for inflammation and immunology indications in patients living with autoimmune diseases. It develops JADE101, a monoclonal antibody to block the A PRoliferation Inducing Ligand protein, which is in phase 1 clinical trial. The company also develops JADE201 and JADE-003, which are in preclinical development stage. Jade Biosciences, Inc. has a collaboration agreement with Paragon Therapeutics, Inc. Jade Biosciences, Inc. is based in Waltham, Massachusetts.

Recent Insider Trades

NameTypeSharesPriceDate
Eisner Mark 0 — 2026-06-25
Eisner Mark A-Award 47,675 $21.81 2026-06-25
CAIN CHRISTOPHER W. A-Award 34,843 $15.22 2026-06-09
DOBMEIER ERIC A-Award 34,843 $15.22 2026-06-09
Klein Lawrence Otto A-Award 34,843 $15.22 2026-06-09

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms